Brought to you by 
Horizon Pharma nets $144mm through notes offering
02 Dec 2013
Executive Summary
Horizon Pharma Inc. (pain and inflammation therapies) netted $144mm through the private sale of 5% senior notes due 2018. The notes convert into common stock at a rate of 186.4 shares per $1k principal amount, or $5.36 per share. Horizon's stock was averaging $4.40 at the time of the sale.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Convertible Debt
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Horizon Pharma nets $144mm through notes offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice